Camrelizumab, chemo and Ivarmacitinib for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of immunotherapy (camrelizumab), chemotherapy, and a targeted drug (ivarmacitinib) before surgery for esophageal cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have esophageal squamous cell cancer that can be surgically removed.
- You are between 18 and 75 years old.
- Your cancer is at stage II to IVA (early to locally advanced).
- You are in good physical condition (ECOG 0-1, meaning you can do most daily activities).
- You do not have cancer that has spread to other parts of the body.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (ivonescimab, also called AK112) combined with chemotherapy before surgery for people with esophageal squamous cell cancer that can be completely removed. The goal is to see if adding immunotherapy before surgery helps shrink the tumor and improve outcomes.
This trial tests a drug called Adebrelimab combined with chemotherapy before surgery for esophageal cancer. It aims to shrink the tumor and make it easier to remove completely.
This trial tests a combination of two drugs (interferon gamma and camrelizumab) given before surgery for a certain type of esophageal cancer. It aims to see if this combination can shrink the tumor and improve outcomes.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.
This trial tests a combination of immunotherapy (adebrelimab) plus standard chemotherapy and radiation for people with advanced esophageal cancer that cannot be removed by surgery. The goal is to see if adding the immunotherapy before and during chemoradiation helps control the cancer better.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.